Methimazole inhibits CXC chemokine ligand 10 secretion in human thyrocytes

Journal of Endocrinology

Volumn 195, Issue 1, 2007, Pages 145-155

  Crescioli, C ^a   Cosmi, L ^a   Borgogni, E ^a   Santarlasci, V ^a   Gelmini, S ^a   Sottili, M ^a   Sarchielli, E ^a   Mazzinghi, B ^a   Francalanci, M ^a   Pezzatini, A ^a   Perigli, G ^a   Vannelli, G B ^a   Annunziato, F ^a   Serio, M ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GAMMA INTERFERON RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MEMBRANE RECEPTOR; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; ROSIGLITAZONE; THIAMAZOLE; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; AUTOIMMUNE DISEASE; CELL ISOLATION; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG POTENCY; DRUG TARGETING; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL DESIGN; FLOW CYTOMETRY; GOITER; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; RECEPTOR UPREGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SUPERNATANT; TH1 CELL; THYROID CELL; THYROID DISEASE; THYROID GLAND;

ANTITHYROID AGENTS; CELLS, CULTURED; CHEMOKINE CXCL10; DEPRESSION, CHEMICAL; FLOW CYTOMETRY; GOITER, NODULAR; HUMANS; INTERFERON TYPE II; METHIMAZOLE; NF-KAPPA B; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; THIAZOLIDINEDIONES; THYROID GLAND; TUMOR NECROSIS FACTOR-ALPHA;

EID: 35848971017     PISSN: 00220795     EISSN: None     Source Type: Journal    
DOI: 10.1677/JOE-07-0240     Document Type: Article

References (45)

1. Aniszewski JP, Valyasevi RW & Bahn RS 2000 Relationship between disease duration and predominant orbital T cell subset in Graves' disease. Journal of Clinical Endocrinology and Metabolism 85 776-780.
2. Annunziato F, Cosmi L, Liotta F, Lazzeri E, Manetti R, Vanini V, Romagnani P Maggi E & Romagnani S 2002 Phenotype, localization, and mechanism of suppression of CD4(+)CD25(+) human thymocytes. Journal of Experimental Medicine 196 379-387.
3. Antonelli A, Rotondi M, Fallahi F, Romagnani P, Ferrari SM, Buonamano A, Ferrannini E & Serio, M 2004 High levels of circulating CXCL10 are associated with chronic autoimmume thyroiditis and hypothyroidism. Journal of Clinical Endocrinology and Metabolism 89 5496-5499.
4. Antonelli A, Rotondi M, Fallahi P, Romagnani P, Ferrari SM, Paolicchi A, Ferrannini E & Serio M 2005 Increase of interferon-gamma inducible α-chemokine CXCL10 but not beta chemokine CCL2 serum levels in chronic autoimmune thyroiditis. European Journal of Endocrinology 152 171-177.
5. Antonelli A, Fallahi P, Rotondi M, Ferrari SM, Romagnani P, Grosso M, Ferrannini E & Serio M 2006a Increased serum CXCL10 in Graves' disease or autoimmune thyroiditis is associated with hyper- or hypothyroidism per se, but is specifically sustained by the autoimmune, inflammatory process. European Journal of Endocrinology 154 651-658.
6. Antonelli A, Fallai P, Rotondi M, Ferrari SM, Serio M & Miccoli P 2006 b Serum levels of the interferon-γ-inducible α-chemokine CXCL10 in patients with active Graves' disease, and modulation by methimazole therapy and thyroidectomy. British Journal of Surgery 93 1226-1231.
7. Antonelli A, Rotondi M, Fallahi P, Romagnani P, Ferrari SM, Barani L, Ferrannini E & Serio M 2006c Increase of interferon-γ-inducible CXC chemokine CXCL10 serum levels in patients with active Graves'disease, and modulation by methimazole therapy. Clinical Endocrinology 64 189-195.
8. Antonelli A, Rotondi M, Ferrari SM, Fallahi P, Romagnani P, Franceschini SS, Serio M & Ferrannini E 2006d Interferon-γ-inducible α-chemokine CXCL10 involvement in Graves' ophthalmopathy: modulation by peroxisome proliferator-activated receptor-γ agonists. Journal of Clinical Endocrinology and Metabolism 91 614-620.
9. Antonelli A, Rotondi M, Fallahi P, Grosso M, Boni G, Ferrari SM, Romagnani P, Serio M, Mariani G & Ferrannini E 2007 Iodine-131 given for therapeutic purposes modulates differently interferon-γ-inducible α-chemokine CXCL10 serum levels in patients with active Graves' disease or toxic nodular goiter. Journal of Clinical Endocrinology and Metabolism 92 1485-1490.
10. Aust G, Sittig D, Steinert M, Lamesch P & Lohmann T 2002 Graves' disease is associated with an altered CXCR3 and CCR5 expression in thyroid-derived compared to peripheral blood lymphocytes. Clinical and Experimental Immunology 127 479-485.
11. Campbell IW 2005 The clinical significance of PPAR gamma agonism. Current Molecular Medicine 5 349-363.
12. Campbell JD, Gangur V, Simons FE & HayGlass KT 2004 Allergic humans are hyporesponsive to a CXCR3 ligand-mediated Th1 immunity-promoting loop. FASEB Journal 18 329-331.
13. De Lean A, Munson PJ & Rodbard D 1978 Simultaneous analysis of families of sigmoidal curves: application to bioassay, radioligand assay, and physiological dose-response curves. American Journal of Physiology 235 E97-E102.
14. Diez JJ, Hernanz A, Medina S, Bayon C & Iglesias P 2002 Serum concentrations of tumour necrosis factor-α (TNF-α) and soluble TNF-α receptor p55 in patients with hypothyroidism and hyperthyroidism before and after normalization of thyroid function. Clinical Endocrinology 57 515-521.
15. Garcia-Lopez MA, Sancho D, Sanchez-Madrid F & Marazuela M 2001 Thyrocytes from autoimmune thyroid disorders produce the chemokines IP-10 and Mig and attract CXCR3 + lymphocytes. Journal of Clinical Endocrinology and Metabolism 86 5008-5016.
16. Gilmore TD 2006 Introduction to NF-κB: players, pathways, perspectives. Oncogene 25 6680-6684.
17. Gosset P, Charbonnier AS, Delerive P, Fontaine J, Staels B, Pestel J, Tonnel AB & Trottein F 2001 Peroxisome proliferator-activated receptor activators affect the maturation of human monocyte-derived dendritic cells. European Journal of Immunology 31 2857-2865.
18. Kang HC, Ohmori M, Harii N, Endo T & Onaya T 2001 Pax8 is essential for regulation of the thyroglobulin gene by transforming growth factor-betal. Endocrinology 142 267-275.
19. Kemp EH, Metcalfe RA, Smith KA, Woodroofe MN, Watson PF & Weetman AP 2003 Detection and localization of chemokine gene expression in autoimmune thyroid disease. Clinical Endocrinology 59 207-213.
20. Krakauer T & Oppenheim JJ 1993 IL-1 and rumor necrosis factor-α each up-regulate both the expression of IFN-γ receptors and enhance IFN-γ-induced HLA-DR expression on human monocytes and a human monocytic cell line (THP-1). Journal of Immunology 150 1205-1211.
21. Laurberg P 2006 Remission of Graves' disease during anti-thyroid drug therapy. Time to reconsider the mechanism? European Journal of Endocrinology 155 783-786.
22. -ΔΔCt method. Methods 25 402-408.
23. Marchant B, Alexander WD, Lazarus JH, Lees J & Clark DH 1972 The accumulation of 35 S-antithyroid drugs by the thyroid gland. Journal of Clinical Endocrinology and Metabolism 34 847-851.
24. Marx N, Mach F, Sauty A, Leung JH, Sarafi MN, Ransohoff RM, Libby P, Plutzky J & Luster AD 2000 Peroxisome proliferator-activated receptor γ activators inhibit IFNγ-induced expression of the T cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells. Journal of Immunology 164 6503-6508.
25. Mc Gregor AM, Petersen MM, McLachlan SM, Rooke P, Smith BR & Han R 1980 Carbimazole and the autoimmune, response in Graves' disease. New England Journal of Medicine 303 302-307.
26. Pinchera A, Liberti P, Martino E, Fenzi GF, Grasso L, Rovis L, Banchieri L & Doria G 1969 Effects of antithyroid therapy on the long-acting thyroid stimulator and the antithyroglobulin antibodies. Journal of Clinical Endocrinology and Metabolism 29 231-238.
27. Romagnam P, Annunziato F, Lasagni L, Lazzeri E, Beltrame C, Francalanci M, Uguccioni, Galli G, Cosmi L, Maurenzig L et al. 2001 Cell cycle dependent expression of CXC chemokine receptor 3 by endothelial cells mediates angiostatic activity. Journal of Clinical Investigation 107 53-63.
28. Romagnam P, Rotondi M, Lazzeri E, Lasagni L, Francalanci M, Buonamano A, Milani S, Vitti P, Chiovato L, Tonacchera M et al. 2002 Expression of IP-10/CXCL10 and Mig/CXCL9 in the thyroid and increased serum levels oflP-10/CXCL10 in the serum of subjects with recent onset Graves' disease. American Journal of Physiology 161 195-206.
29. Romagnam P, Lasagni L, Annunziato F, Serio M & Romagnani S 2004 CXC chemokines: the regulatory link between inflammation and angiogenesis. Trends in Immunology 25 201-209.
30. Rotondi M, Lazzeri E, Romagnani P & Serio M 2003 Role for interferon-γ inducible chemokines in endocrine autoimmunity: an expanding field. Journal of Endocrinological Investigation 26 177-180.
31. Rotondi M, Falorni A, De Bellis A, Laureti S, Ferruzzi P, Romagnani P, Buonamano A, Lazzeri E, Crescioli C, Mannelli M et al. 2005 Elevated serum interferon-γ-inducible chemokine-10/CXC chemokine ligand-10 in autoimmune primary adrenal insufficiency and in vitro expression in human adrenal cells primary cultures after stimulation with proinflammatory cytokines. Journal of Clinical Endocrinology and Metabolism 90 2357-2367.
32. Rotondi M, Chiovato L, Romagnani S, Serio M & Romagnani P 2007 Role of chemokines in endocrine autoimmune diseases. Endocrine Reviews 28 492-520.
33. Sana TR, Janatpour MJ, Sathe M, McEvoy LM & McClanahan TK 2005 Microarray analysis of primary endothelial cells challenged with different inflammatory and immune cytokines. Cytokine 9 256-269.
34. Schaefer KL, Denevich S, Ma C, Cooley SR, Nakajima A, Wada K, Schlezinger J, Sherr D & Saubermann LJ 2005 Intestinal antiinflammatory effects of thiazolidenedione, peroxisome proliferator-activated receptor-γ ligands on T helper type 1 chemokine regulation include nontranscriptional control mechanisms. Inflammatory Bowel Diseases 11 244-252.
35. Starkey K, Heufelder A, Baker G, Joba W, Evans M, Davies S & Ludgate M 2003 Peroxisome proliferator-activated receptor-γ in thyroid eye disease: contraindication for thiazolidinedione use? Journal of Clinical Endocrinology and Metabolism 88 55-59.
36. Su CG, Wen X, Bailey ST, Jiang W, Rangwala SM, Keilbaugh SA, Flanigan A, Murthy S, Lazar MA & Wu GD 1999 A novel therapy for colitis utilizing PPAR-γ ligands to inhibit the epithelial inflammatory response. Journal of Clinical Investigation 104 383-389.
37. Valyasevi RW, Harteneck DA, Dutton CM & Bahn RS 2002 Stimulation of adipogenesis, peroxisome proliferator-activeted receptor-γ (PPARγ), and thyrotropin receptor by PPARγ agonist in human orbital preadipocyte fibroblasts. Journal of Clinical Endocrinology and Metabolism 87 2352-2358.
38. Vannelli GB, Ensoli F, Zonefrati R, Kubota Y, Arcangeli A, Becchetti A, Camici G, Barni T, Thiele CJ & Balboni GC 1995 Neuroblast long-term cell cultures from human fetal olfactory epithelium respond to odors. Journal of Neuroscience 15 4382-4394.
39. Volpé R, 2001 The inummomodulatory effects of anti-thyroid drugs are mediated via actions on thyroid cells, affecting thyrocyte-immunocyte signalling: a review. Current Pharmaceutical Design 7 451-460.
40. Wakelkamp IM, Bakker O, Baldeschi L, Wiersinga WM & Prummel MF 2003 TSH-R expression and cytokine, profile in orbital tissue of active vs. inactive Graves' ophthalmopathy patients. Clinical Endocrinology 58 280-287.
41. Watson PF, Pickerill AP, Davies R & Weetman AP 1995 Semiquantitative analysis of IL-1a, IL-6 and IL-8 mRNA expression by human thyrocytes. Journal of Molecular Endocrinology 15 11-21.
42. Weetman AP 2003 Autoimmune thyroid disease: propagation and progression. European Journal of Endocrinology 148 1-9.
43. Weetman AP 2004 Cellular immune responses in autoimmune thyroid disease. Clinical Endocrinology 61 405-413.
44. Weetman AP & McGregor AM 1994 Autoimmune thyroid disease: further developments in our understanding. Endocrine Reviews 15 788-830.
45. Zlotnik A & Yoshie O 2000 Chemokines: a new classification system and their role in immunity. Immunity 12 121-127.